2MW7061 / Mabwell (Shanghai) Biosci - LARVOL DELTA

2MW7061, a novel LILRB4xCD3 bispecific T-cell engager targeting monocytic acute myeloid leukemia (AACR 2025) - "2MW7061 is a bispecific T-cell engager with potent LILRB4-dependent anti-tumor activity in preclinical models of monocytic AML. Its low nonspecific T-cell binding and favorable safety profile in non-human primates support its continued development as a promising therapeutic candidate for clinical evaluation in AML."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CRP • LILRB4

2MW7061, a novel LILRB4xCD3 bispecific T-cell engager targeting monocytic acute myeloid leukemia (PRNewswire) - "In preclinical models of AML (acute myeloid leukemia), 2MW7061 showed strong anti-tumor activity. Non-primate toxicology studies indicate a favorable safety profile, highlighting its therapeutic potential for treating AML patients."

Preclinical • Acute Myelogenous Leukemia

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Mabwell...announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held in Chicago, USA, from April 25-30, 2025."

Preclinical • Acute Myelogenous Leukemia • Oncology • Solid Tumor